Catalyst Capital Advisors’s Q32 Bio QTTB Stock Holding History

Catalyst Capital Advisors’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18	Closed	-$7K	–	544
2018 Q2	$7K	Buy	18 +6	+50%	+$2.15K	﹤0.01%	410
2018 Q1	$4K	Buy	+12	New	+$4.04K	﹤0.01%	432

Other funds holding QTTB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Catalyst Capital Advisors's QTTB Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Q32 Bio (QTTB) in Q3 2018, closing a stake of 18 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in QTTB in Q1 2018 and held it in 2 quarters. The position peaked at $7K in Q2 2018. 50 funds tracked by Wall St. Rank hold QTTB as of Q3 2018.

Catalyst Capital Advisors reported no remaining Q32 Bio position as of Q3 2018 after selling out during the quarter.
Catalyst Capital Advisors sold 18 Q32 Bio shares in Q3 2018, an estimated $7K.
Catalyst Capital Advisors first reported a position in Q32 Bio in Q1 2018 and held it in 2 quarters.
Catalyst Capital Advisors's Q32 Bio position peaked at $7K in Q2 2018.
50 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.